太龙药业：拟获江药控股现金认购不超454345765.44元股份

Core Viewpoint - TaiLong Pharmaceutical announced a share subscription agreement with Jiang Pharmaceutical Group, indicating a strategic partnership and capital infusion for future growth [2] Group 1: Agreement Details - The agreement involves Jiang Pharmaceutical Group subscribing to A-shares issued by TaiLong Pharmaceutical for the year 2025 [2] - The total subscription amount is capped at 454,345,765.44 yuan, equivalent to approximately 454.35 million yuan [2] - The number of shares to be subscribed is not to exceed 74,605,216 shares [2]